You can choose the size of the video you would like to embed below. Next, copy the embed code that is available in the box below. Paste this code on to your website to display the video.
If you experience problems embedding videos, please contact us.
Financial News Network
January 28, 2011 AT 4:09 PM
Apricus Biosciences (APRI) today reported that its research and development team at its NexMed, USA subsidiary will be presenting data that will demonstrate the use of the APRI's proprietary NexACT technology to improve less permeable or less soluable drugs, at the Controlled Release Society Product Development Forum for Poorly Soluble Drugs, being held January 27 to 29, 2011, in Miami, Florida. The company claims that the results demonstrates that the NexACT technology may be used to enhance the oral bioavailability of some of the less permeable and less soluble drugs that are currently on the market. APRI further believes this other application for our NexACT technology could be used with any of its future proprietary drug candidates, or may be applied to a broader range of generic drugs and proprietary drugs owned by others. Shares are down 1.35% or $0.05 to $3.80.